mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2016-1-67-71mrj-675Research ArticleОБЗОРЫREVIEWSМесто и значение нестероидных противовоспалительных препаратов в терапии остеоартрозаThe place and value of nonsteroidal anti-inflammatory drugs in the therapy of osteoarthritisБадокинВ. В.BadokinV. V.

123836, Москва, Баррикадная ул., 2/1

2/1, Barrikadnaya St., Moscow 123836

ГБОУ ДПО «Российская медицинская академия последипломного образования»РоссияRussian Medical Academy of Postgraduate EducationRussian Federation2016240320161016771Copyright © Бадокин В.В., 20162016Бадокин В.В.Badokin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/675

Целесообразность применения нестероидных противовоспалительных препаратов (НПВП) при остеоартрозе (ОА) обусловлена прежде всего наличием персистирующего воспаления в тканях сустава, которое способствует прогрессированию структурных изменений гиалинового хряща, а также его ведущего клинического проявления – болевого синдрома, обусловленного поражением различных структур сустава. НПВП являются основными симптом-модифицирующими препаратами быстрого действия в лечении ОА. Мелоксикам обладает высокой антивоспалительной и аналгезирующей активностью. Влияние мелоксикама на метаболизм гиалинового хряща позволяет рассматривать его как потенциальный хондропротективный препарат. В краткосрочных и долгосрочных исследованиях продемонстрирована его хорошая переносимость, в том числе у больных с полиморбидностью. Использование мелоксикама не сопровождается значительным нарастанием риска развития кардиальных и почечных осложнений. Высокая терапевтическая активность мелоксикама наряду с низким уровнем нежелательных реакций обусловливает фармакоэкономическую целесообразность его применения.

The reasonability of using nonsteroidal anti-inflammatory drugs (NSAIDs) in osteoarthritis (OA) is due mainly to persistent articular tissue inflammation that contributes to the progression of structural changes in the hyaline cartilage, as well as its leading clinical manifestation – pain syndrome caused by damage to different articular structures. NSAIDs are basic rapid-acting symptom-modifying drugs in the treatment of OA. Meloxicam has high anti-inflammatory and analgesic activities. The effect of meloxicam on hyaline cartilage metabolism permits one to consider it as a potential chondroprotective agent. Short- and long-term investigations have demonstrated its good tolerability, including that in patients with polymorbidity. The use of meloxicam does not increase the risk of cardiac and renal complications. The high therapeutic activity of meloxicam along with the low level of adverse reactions determines the pharmacoeconomic expediency of its use.

остеоартрознестероидные противовоспалительные препаратымелоксикамперсистирующее воспалениехондропротекциябезопасностьosteoarthritisnonsteroidal anti-inflammatory drugsmeloxicampersistent inflammationchondroprotectionsafetyReferencesБадокин ВВ. Значение воспаления в развитии и течении остеоартроза. Consilium medicum 2009;11(9):91-5. [Badokin VV. The importance of inflammation in the development and course of osteoarthritis. Consilium medicum 2009;11(9):91-5. (In Russ.)].Бадокин ВВ. Значение воспаления в развитии и течении остеоартроза. Consilium medicum 2009;11(9):91-5. [Badokin VV. The importance of inflammation in the development and course of osteoarthritis. Consilium medicum 2009;11(9):91-5. (In Russ.)].Brandt KD. Diagnosis and nonsurgical management of osteoarthritis. Proffesional communications; 2000. 304 p.Brandt KD. Diagnosis and nonsurgical management of osteoarthritis. Proffesional communications; 2000. 304 p.Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec;62(12):1145-55.Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec;62(12):1145-55.Arden N, Nevitt MC. Osteoarthrosis: epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25.Arden N, Nevitt MC. Osteoarthrosis: epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25.Reid JL, Morton DJ, Wingard DL, et al. Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002–2006. Ethn Dis. 2010 Autumn;20(4):416-22.Reid JL, Morton DJ, Wingard DL, et al. Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002–2006. Ethn Dis. 2010 Autumn;20(4):416-22.van den Berg WB. Pathophisiology of osteoarthritis. Joint Bone Spine. 2000;67(6):555-6.van den Berg WB. Pathophisiology of osteoarthritis. Joint Bone Spine. 2000;67(6):555-6.Кашеварова НГ. Остеоартроз коленных суставов: факторы риска прогрессирования заболевания при пятилетнем проспективном наблюдении. Автореф. дисс. канд. мед. наук. М., 2014. 22 с. [Kashevarova NG. Knee osteoarthritis: risk factors for progression of the disease with fiveyear prospective observation. Autoref. diss. cand. med. sci. Moscow, 2014. 22 p.]Кашеварова НГ. Остеоартроз коленных суставов: факторы риска прогрессирования заболевания при пятилетнем проспективном наблюдении. Автореф. дисс. канд. мед. наук. М., 2014. 22 с. [Kashevarova NG. Knee osteoarthritis: risk factors for progression of the disease with fiveyear prospective observation. Autoref. diss. cand. med. sci. Moscow, 2014. 22 p.]Цветкова EC. Оценка эффективности применения мовалиса при остеоартрозе и ревматоидном артрите (данные многоцентрового российского исследования). Научно-практическая ревматология. 2005;43(2):29-32. [Tsvetkova EC. Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a Russian multicentr study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2005;43(2):29-32. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2005-1521Цветкова EC. Оценка эффективности применения мовалиса при остеоартрозе и ревматоидном артрите (данные многоцентрового российского исследования). Научно-практическая ревматология. 2005;43(2):29-32. [Tsvetkova EC. Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a Russian multicentr study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2005;43(2):29-32. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2005-1521Sokolove J, Lepus CM. Role of Inflammation in the Pathogenesis of Osteoarthritis. LatestSokolove J, Lepus CM. Role of Inflammation in the Pathogenesis of Osteoarthritis. LatestFindings and Interpretations. Ther Adv Musculoskelet Dis. 2013 Apr;5(2):77-94. doi: 10.1177/1759720X12467868.Findings and Interpretations. Ther Adv Musculoskelet Dis. 2013 Apr;5(2):77-94. doi: 10.1177/1759720X12467868.Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, Inflammatory Disease. Arthritis Rheum. 2001 Jun;44(6):1237-47.Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, Inflammatory Disease. Arthritis Rheum. 2001 Jun;44(6):1237-47.Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloхicam compared to diclofenac in osteoarthritis hftients. International MELISSA Study Group. Meloхicam Large Scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45.Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloхicam compared to diclofenac in osteoarthritis hftients. International MELISSA Study Group. Meloхicam Large Scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45.Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability on the selective cyclooхygenase (COХ)-2 inhibitor, meloхicam, compared with piroхicam: results of the Safety and Efficacy Large scale Evalution of COХ inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946-51.Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability on the selective cyclooхygenase (COХ)-2 inhibitor, meloхicam, compared with piroхicam: results of the Safety and Efficacy Large scale Evalution of COХ inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946-51.Gagnier P, Singh G, Reed JI, et al. The effect of meloхicam versus usual care NSAIDS for the treatment of osteoarthritis in usual care setting. The results of the IMPROVE trial. Ann Rheum Dis 2001;60(suppl 1):235.Gagnier P, Singh G, Reed JI, et al. The effect of meloхicam versus usual care NSAIDS for the treatment of osteoarthritis in usual care setting. The results of the IMPROVE trial. Ann Rheum Dis 2001;60(suppl 1):235.Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation. 2002Jun;26(3):139-42.Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation. 2002Jun;26(3):139-42.Mastbergen SC, Biijlsma JW, Lefeber FP. Selective COX-2 inhibition is favorable to human early and latestage osteoarthritis cartilage: a human in vitro study. Osteoarthritis Cartilage. 2005 Jun;13(6):519-26.Mastbergen SC, Biijlsma JW, Lefeber FP. Selective COX-2 inhibition is favorable to human early and latestage osteoarthritis cartilage: a human in vitro study. Osteoarthritis Cartilage. 2005 Jun;13(6):519-26.Recommendations for the registration of drug used in the treatment of osteoarthritis. Ann Rheum Dis. 1996 Aug;55(8):552-7.Recommendations for the registration of drug used in the treatment of osteoarthritis. Ann Rheum Dis. 1996 Aug;55(8):552-7.Zeidler H, Kaltwasser JP, Leonard JP, et al Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13,307 Patients in Germany. J Clin Rheumatol. 2002 Dec;8(6):305-15.Zeidler H, Kaltwasser JP, Leonard JP, et al Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13,307 Patients in Germany. J Clin Rheumatol. 2002 Dec;8(6):305-15.Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloхicam of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000 Dec;131(7):1413-21.Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloхicam of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000 Dec;131(7):1413-21.Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно-практическая ревматология. 2015;53(1):63–68. [Tsvetkova ES, Ionichenok NG, Denisov LN. Current pharmacotherapy for knee osteoarthritis: Specific features of symptomatic and disease modifying effects. Communication 1. Specific features of the symptomatic effects of current drugs to treat knee ostheoarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(1):63–68. (in Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2015-63-68Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно-практическая ревматология. 2015;53(1):63–68. [Tsvetkova ES, Ionichenok NG, Denisov LN. Current pharmacotherapy for knee osteoarthritis: Specific features of symptomatic and disease modifying effects. Communication 1. Specific features of the symptomatic effects of current drugs to treat knee ostheoarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(1):63–68. (in Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2015-63-68Degner F, Lanes S, van Ryn J, et al. Pharmacological and clinical profile mekrncam. In: Vane JR, Botting RM, editors. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press; 2001. 423-33.Degner F, Lanes S, van Ryn J, et al. Pharmacological and clinical profile mekrncam. In: Vane JR, Botting RM, editors. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press; 2001. 423-33.Huskisson EC, Ghozlan R, Kurthen R, et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol. 1996 Apr;35 Suppl 1:29-34.Huskisson EC, Ghozlan R, Kurthen R, et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol. 1996 Apr;35 Suppl 1:29-34.Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011 Sep;4(5):605-21. doi: 10.1586/ecp.11.36.Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011 Sep;4(5):605-21. doi: 10.1586/ecp.11.36.Мазуров ВИ. Применение мелоксикама (Мовалиса) у больных с ревматическими заболеваниями с сопутствующей ишемической болезнью сердца. Клиническая медицина. 2004;(12):54-9. [Mazurov VI. The use of meloxicam (Movalis) in patients with rheumatic disease with concomitant coronary artery disease. Klinicheskaya meditsina. 2004;(12):54-9. (In Russ.)].Мазуров ВИ. Применение мелоксикама (Мовалиса) у больных с ревматическими заболеваниями с сопутствующей ишемической болезнью сердца. Клиническая медицина. 2004;(12):54-9. [Mazurov VI. The use of meloxicam (Movalis) in patients with rheumatic disease with concomitant coronary artery disease. Klinicheskaya meditsina. 2004;(12):54-9. (In Russ.)].Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescribtion-Events Monitoring (PEM) data. Rheumatology (Oxford). 2003 Nov;42(11):1354-64. Epub 2003 Jul 16.Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescribtion-Events Monitoring (PEM) data. Rheumatology (Oxford). 2003 Nov;42(11):1354-64. Epub 2003 Jul 16.Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010 Apr;32(4): 667-77. doi: 10.1016/j.clinthera.2010.04.009.Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010 Apr;32(4): 667-77. doi: 10.1016/j.clinthera.2010.04.009.Van Ryn J, Kink-Eiband M, Kuritsch I, et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol. 2004 Jul;44(7):777-84.Van Ryn J, Kink-Eiband M, Kuritsch I, et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol. 2004 Jul;44(7):777-84.Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal antiinflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015 May;26(4):285-91. doi: 10.1016/j.ejim.2015.03.008. Epub 2015 Apr 8.Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal antiinflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015 May;26(4):285-91. doi: 10.1016/j.ejim.2015.03.008. Epub 2015 Apr 8.Афанасьева ЕВ, Белоусов ДЮ, Цветкова ЕС. Фармакоэкономический анализ применения препарата Мовалис у больных остеоартрозом и ревматоидным артритом. Качественная клиническая практика 2015;(1):66-76. [Afanas'eva EV, Belousov DYu, Tsvetkova ES. Pharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritis. Kachestvennaya klinicheskaya praktika 2015;(1):66-76. (In Russ.)].Афанасьева ЕВ, Белоусов ДЮ, Цветкова ЕС. Фармакоэкономический анализ применения препарата Мовалис у больных остеоартрозом и ревматоидным артритом. Качественная клиническая практика 2015;(1):66-76. [Afanas'eva EV, Belousov DYu, Tsvetkova ES. Pharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritis. Kachestvennaya klinicheskaya praktika 2015;(1):66-76. (In Russ.)].

The authors declare that there are no conflicts of interest present.